Director of HKAP, Professor Aiping Lyu, Dr. Kennedy Y.H. Wong Endowed Professor, has been elected as a foreign member of The Academy of Europe. Congratulations!
Professor Lyu is a world-leading scientist in aptamer-based translational medicine and drug discovery. He is not only working on basic research that demonstrates novel precision medicine-based therapeutic strategies for rheumatic disease treatment, but also on translational research in collaboration with the pharmaceutical industry for the development of novel therapeutic agents. He is the director of the first aptamer R&D platform in Guangdong-Hong Kong-Macao Greater Bay Area of China, which has attracted aptamer pharmaceutical industries to establish "Aptamer Drug Valley" in the Hong Kong Science Park. He has developed the world's first osteoblast-targeting nucleic acid aptamer. His discovery of the therapeutic aptamer targeting Sclerostin loop3 has been granted Orphan Drug Designation by US FDA (DRU-2019-6966) for promoting bone formation in osteogenesis imperfect. He has also developed the first aptamer-Paclitaxel conjugates, which showcased a precision medicine-based personalized Paclitaxel for targeting specific cancer types, which is currently being developed into anti-cancer therapeutics by a pharmaceutical company.
The membership page of Prof. Lyu can be found at this link Academy of Europe: Lyu Aiping (ae-info.org).
